Hearing Tracker·Industry news·Research (general)·21h agoSensorion Names GJB2 Hearing Loss Therapy as Lead Program; Ends OTOF TrialThe strategic shift signals that GJB2-related hereditary hearing loss — the most prevalent form of genetic deafness — is becoming a priority target in the emerging gene therapy landscape, while setbacks in OTOF programs highlight the difficulty of translating inner-ear gene...
Hearing Health Matters·Press release·Research (general)·1d agoSensorion Advances GJB2 Hearing Loss Gene Therapy Following Regulatory MilestonesGJB2 mutations are the most common cause of inherited hearing loss, so a gene therapy entering clinical-trial stages represents a meaningful step toward a potential biological treatment option.＋Save
